Additionally, the greater efficacy of GM-CSF vaccination in the adjuvant setting may result in eradication of residual micro-metastasis if present, and higher frequencies of functional tumor-specific T cells may be due to lower tumor burden and ultimately less tumor-mediated immune suppression compared to metastatic disease (20). This evidence concerns the gene CSF2 and neoplasm.